{"id":15141,"date":"2026-02-13T16:11:58","date_gmt":"2026-02-13T15:11:58","guid":{"rendered":"https:\/\/www.cbd.fr\/blog\/?p=15141"},"modified":"2026-02-13T16:12:00","modified_gmt":"2026-02-13T15:12:00","slug":"liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal","status":"publish","type":"post","link":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/","title":{"rendered":"Liver and CBD: what do clinical trials and pharmacovigilance really reveal?"},"content":{"rendered":"<p>\nCannabidiol (CBD), a key component of medical cannabis, is generating increasing interest for its potential therapeutic effects. The growing number of clinical trials and the accumulation of pharmacovigilance data are prompting a better understanding of its safety profile, particularly its effect on the liver. What signals are emerging? How should we interpret the drug interactions and adverse effects reported in the scientific literature? Let&#8217;s explore the answers offered by recent research. What do we know about CBD metabolism in the liver? The liver plays a central role in the transformation of CBD after ingestion. Cannabinoids are metabolized there primarily via cytochrome P450 enzymes, a family of enzymes essential for the breakdown of chemical substances, including medications. This hepatic metabolism determines the bioavailability of cannabidiol and greatly influences its tolerability. In both animals and humans, clinical trials show that most CBD is converted by isoforms such as CYP3A4 or CYP2C19. These enzymes can become saturated, especially at high doses, which alters the elimination rate of cannabidiol and other molecules that utilize the same hepatic pathways. Some recent findings also highlight individual variability, particularly related to patient genetics. The liver metabolizes more than 90% of absorbed CBD. Interindividual differences depend on the patient&#8217;s enzyme profile. Several common medications share these same cytochromes. What adverse effects on the liver have been observed in clinical trials? The majority of clinical trials conducted on CBD show a very good liver safety profile at low to moderate doses. However, the administration of high concentrations, sometimes required for certain therapeutic effects, has raised several cases of <strong>Transient elevation of liver enzymes<\/strong> <strong>These elevations, often asymptomatic, are among the main<\/strong>adverse effects <strong>monitored in scientific protocols.<\/strong> <strong>In the context of current research, it is also worth noting that new studies are highlighting the implications of<\/strong> CBD on the body <strong><\/strong> particularly regarding its anti-inflammatory effects, its interaction with anxiety, and its anticancer potential. These increases mainly concern <strong>transaminases (ALT, AST)<\/strong> <strong>, considered early markers of<\/strong>liver stress <strong>. In almost all the cases described, these changes were reversible upon discontinuation or reduction of the<\/strong> cannabidiol dose <strong><\/strong> However, a few cases of\n<\/p>\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_84 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Sommaire<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #43b981;color:#43b981\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #43b981;color:#43b981\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#mild_acute_hepatitis\" >mild acute hepatitis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#or_generating\" >or generating<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#is_well_tolerated_by_the\" >is well tolerated by the<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#Even_without_a_specific_condition_or_treatment_minimal_vigilance_is_recommended_to_monitor_the_liver\" >Even without a specific condition or treatment, minimal vigilance is recommended to monitor the liver.<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"mild_acute_hepatitis\"><\/span>mild acute hepatitis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>\n <strong>have been noted, occurring primarily during co-administration with other molecules having a<\/strong> similar metabolism <strong><\/strong> . Adverse Effect <strong>Reported Frequency<\/strong> Severity <strong>Elevated Transaminases<\/strong>3-9% (high doses) <strong>Almost always mild<\/strong> Nausea\/Vomiting\n<\/p>\n<p>\n5-10% <strong>Mild to moderate<\/strong> Acute Hepatitis <strong>(rare)<\/strong> &lt;1% <strong>May require discontinuation of treatment<\/strong> How to monitor the liver&#8217;s impact of CBD over time? <strong>Professionals generally recommend regular monitoring of liver function parameters, especially during the first few weeks following the introduction of CBD. This measure reassures both the patient and the prescriber, thus preventing any undetected adverse effects.<\/strong>For individuals already treated with another medication eliminated via the liver, this precaution becomes essential. This involves standard laboratory monitoring, including the measurement of transaminases and bilirubin, repeated according to the patient&#8217;s specific clinical situation. <strong>Why are some people more exposed to the risks?<\/strong> Individual vulnerability stems primarily from the overall health context and exposure to other <strong>medications metabolized by the same cytochrome enzymes.<\/strong>\n<\/p>\n\n<ul>\n  <li><strong>Those with<\/strong> pre-existing liver disease <strong>or the elderly should be even more vigilant, as their<\/strong>liver<\/li>\n  <li>is often less efficient. <strong><\/strong>Genetic differences can amplify or inhibit the<\/li>\n  <li>metabolism of CBD <strong>, altering the benefit-risk balance. Hence the importance, in cases of chronic use or self-medication, of consulting a healthcare professional before introducing<\/strong> cannabidiol <strong>into one&#8217;s routine.<\/strong>Drug interactions: what signals in pharmacovigilance?<\/li>\n<\/ul>\n\n<h2><\/h2>\n<p>\nCannabinoids <strong>, particularly<\/strong> CBD <strong>, present potential risks of<\/strong> drug interactions <strong>via the inhibition or induction of certain<\/strong> cytochrome enzymes in the liver. In practice, this means that if a patient is simultaneously taking a medication metabolized by these same enzymes, their concentration can increase or decrease unpredictably. <strong>National and international pharmacovigilance databases are gradually accumulating reports of unexpected alterations in the efficacy or tolerability of treatments combined with cannabidiol.<\/strong>Anticonvulsants, anticoagulants, and immunosuppressants are among the most affected therapeutic classes.<strong>The effect of CBD on liver metabolism varies depending on the dose.<\/strong>The risks increase with polypharmacy or underlying liver disease. <strong><\/strong> Not all cannabinoids have the same impact on liver cytochromes.\n<\/p>\n<p>\n <a href=\"https:\/\/www.cbd.fr\/blog\/le-cbd-zoom-sur-les-10-dernieres-decouvertes-scientifiques\/\">What concrete examples of interactions exist? In epileptic patients treated with valproate or clobazam, the addition of CBD frequently leads to an increase in adverse effects.<\/a>linked to these molecules, sometimes even requiring a dosage adjustment. Similar cases involve anticoagulant treatments, where increased monitoring of blood tests is systematically recommended. <strong>Beyond potential liver disorders, there are also recent investigations into the anti-inflammatory effects of CBD and its involvement in various medical fields.<\/strong>In the field of cancer, certain anticancer molecules are also affected by these pharmacokinetic changes induced by cannabidiol. <strong>Although no serious adverse events have been documented on a large scale, caution is still advised, especially since clinical trials initiated on this subject are often short-term.<\/strong>How can the risk of drug interactions with CBD be limited? <strong>The doctor-patient dialogue remains the essential cornerstone. Clearly informing patients about all substances consumed, monitoring the clinical response, and adjusting the prescription based on the collected biological results: these practices help prevent most adverse events. When it comes to self-medication, choosing a<\/strong>certified preparation<strong>and favoring<\/strong>low doses <strong>limits exposure. Regular<\/strong>liver function tests\n<\/p>\n\n<table>\n  <tr>\n    <th>at the start of treatment or during a gradual dose increase complement these precautions without hindering the desired benefits.<\/th>\n    <th>Cannabinoids, the liver, and future research perspectives<\/th>\n    <th>As publications accumulate, it appears that only excessive CBD use<\/th>\n  <\/tr>\n  <tr>\n    <td><strong>actually exposes individuals to serious liver toxicity.<\/strong><\/td>\n    <td>The balance between therapeutic effects and risks depends heavily on the individualization of each protocol, adjusting to the state of the liver,<\/td>\n    <td>concomitant treatments,<\/td>\n  <\/tr>\n  <tr>\n    <td><strong>and the patient&#8217;s actual clinical needs.<\/strong><\/td>\n    <td>Research is increasing on the<\/td>\n    <td>selective modulation of cytochrome enzymes<\/td>\n  <\/tr>\n  <tr>\n    <td><strong>using derivatives of<\/strong> Natural or synthetic cannabinoids<i>The challenge lies in isolating those that optimize the benefits of<\/i>medical cannabis<\/td>\n    <td>without increasing the metabolic burden on the<\/td>\n    <td>liver<\/td>\n  <\/tr>\n<\/table>\n\n<h3><span class=\"ez-toc-section\" id=\"or_generating\"><\/span>or generating<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>\nunforeseen drug interactions <strong>.<\/strong>Innovation focuses on <strong>personalization<\/strong>: adapting the molecule, the dosage form, and the dose to each user. <strong>New<\/strong> clinical trials\n<\/p>\n<p>\nin advanced stages are specifically examining the <strong>liver safety of CBD<\/strong>in &#8220;vulnerable&#8221; populations. <strong>Frequently Asked Questions about CBD and the Liver<\/strong> Can CBD damage the liver with daily use? <strong>Current data suggest that<\/strong>moderate CBD consumption\n<\/p>\n\n<h3><span class=\"ez-toc-section\" id=\"is_well_tolerated_by_the\"><\/span>is well tolerated by the<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>\nliver <strong>for most healthy users. The rare<\/strong>adverse effects <strong>observed during<\/strong> clinical trials <strong>mainly concern<\/strong> high doses\n<\/p>\n<p>\n, exceeding those used in everyday life. <strong>Controlling the<\/strong>quality of the product <strong>and adjusting the dose significantly reduces the risk of<\/strong> liver-related side effects.\n<\/p>\n\n<h2><\/h2>\n<p>\nMedical monitoring <strong>is necessary if a<\/strong>maintenance treatment is being used or in cases of <strong>diagnosed liver disease.<\/strong><strong>What are the known drug interactions between CBD and the liver?<\/strong>  <strong>CBD<\/strong>interferes with many\n<\/p>\n<p>\nmedications metabolized by cytochrome P450 enzymes. <strong>This primarily concerns certain<\/strong> antiepileptics, <strong>anticoagulants,<\/strong> <strong>immunosuppressants,<\/strong> <strong>and<\/strong>antidepressants. These are all examples where pharmacovigilance experience <strong>recommends adjusting dosages.<\/strong> Reporting any\n<\/p>\n\n<ul>\n  <li>self-medication <strong>to your doctor helps anticipate potential<\/strong> adverse effects. <strong><\/strong> Regular<\/li>\n  <li>liver function tests <strong>prevent any abnormal increases in<\/strong> transaminases. <strong>Medication<\/strong>Type of interaction observed<\/li>\n  <li>Clobazam <strong>Increased plasma levels, increased sedative potential<\/strong> Warfarin <strong>Potentialization of anticoagulation<\/strong>Should liver function be monitored while taking CBD even without other medication?<\/li>\n<\/ul>\n\n<h3><span class=\"ez-toc-section\" id=\"Even_without_a_specific_condition_or_treatment_minimal_vigilance_is_recommended_to_monitor_the_liver\"><\/span>Even without a specific condition or treatment, minimal vigilance is recommended to monitor the liver.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>\nTolerance <strong>when first using<\/strong> CBD <strong>. A few<\/strong>blood tests <strong>are enough to dispel any doubts or concerns. This is especially true for prolonged use, increasing doses, or in at-risk individuals.<\/strong> Start with small amounts and increase gradually. <strong>Listen to your body&#8217;s reactions to<\/strong> CBD <strong>.<\/strong>Discuss any new or persistent symptoms with a\n<\/p>\n<p>\nhealthcare professional <a href=\"https:\/\/www.cbd.fr\/blog\/le-cbd-zoom-sur-les-10-dernieres-decouvertes-scientifiques\/\">.<\/a>Does CBD offer benefits for the liver in certain conditions? <strong>Currently, no large-scale human study has definitively demonstrated a<\/strong> direct benefit of CBD for liver health <strong>in chronic liver diseases such as non-alcoholic fatty liver disease, viral hepatitis, or cirrhosis. However, some preclinical results in animal models suggest interesting anti-inflammatory and antifibrotic effects. Indeed, CBD appears in several studies to mitigate the progression of liver damage induced by various toxic or infectious agents, due to its antioxidant and endocannabinoid system-modulating properties.<\/strong> <strong>However, the transition to human applications still requires robust evidence from controlled clinical trials to rule out any risk of long-term toxicity or interaction with standard treatments. Therefore, further scientific rigor is necessary before recommending cannabidiol as a &#8220;liver protector.&#8221; Any therapeutic use should be based on informed medical advice, particularly for individuals with chronic liver disease.<\/strong> \n<\/p>\n\n<h3><\/h3>\n<p>\n <strong><\/strong>  <strong><\/strong> \n<\/p>\n<p>\n <strong><\/strong>  <strong><\/strong>  <strong><\/strong>\n<\/p>\n\n<h2><\/h2>\n<p>\n <strong><\/strong>  <strong><\/strong> <strong><\/strong>  <strong><\/strong> <strong><\/strong> \n<\/p>\n<p>\n <strong><\/strong>  <strong><\/strong> <strong><\/strong>  <strong><\/strong><strong><\/strong>\n<\/p>\n\n<ul>\n  <li> <strong><\/strong> <\/li>\n  <li> <strong><\/strong> <strong><\/strong> <\/li>\n<\/ul>\n\n<h2><\/h2>\n\n<div>\n  <div>\n    <h3><\/h3>\n    <div>\n      <div>\n         <strong><\/strong>  <strong><\/strong>  <strong><\/strong>  <strong><\/strong>  <strong><\/strong> \n<ul>\n          <li> <strong><\/strong> <strong><\/strong><\/li>\n          <li> <strong><\/strong>  <strong><\/strong>  <strong><\/strong><\/li>\n        <\/ul>\n      <\/div>\n    <\/div>\n  <\/div>\n  <div>\n    <h3><\/h3>\n    <div>\n      <div>\n         <strong><\/strong>  <strong><\/strong> <strong><\/strong> <strong><\/strong> <strong><\/strong>  <strong><\/strong> <strong><\/strong> \n<ul>\n          <li> <strong><\/strong>  <strong><\/strong><\/li>\n          <li> <strong><\/strong>  <strong><\/strong><\/li>\n        <\/ul>\n        <table>\n          <tr>\n            <th><\/th>\n            <th><\/th>\n          <\/tr>\n          <tr>\n            <td><strong><\/strong><\/td>\n            <td><\/td>\n          <\/tr>\n          <tr>\n            <td><strong><\/strong><\/td>\n            <td><\/td>\n          <\/tr>\n        <\/table>\n      <\/div>\n    <\/div>\n  <\/div>\n  <div>\n    <h3><\/h3>\n    <div>\n      <div>\n         <strong><\/strong>  <strong><\/strong> <strong><\/strong> \n<ol>\n          <li><\/li>\n          <li> <strong><\/strong><\/li>\n          <li> <strong><\/strong><\/li>\n        <\/ol>\n      <\/div>\n    <\/div>\n  <\/div>\n  <div>\n    <h3><\/h3>\n    <div>\n      <div>\n         <strong><\/strong>  <strong><\/strong> \n<br>\n         <strong><\/strong> \n<\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n\n<div class=\"kk-star-ratings kksr-auto kksr-align-left kksr-valign-bottom\"\n    data-payload='{&quot;align&quot;:&quot;left&quot;,&quot;id&quot;:&quot;15141&quot;,&quot;slug&quot;:&quot;default&quot;,&quot;valign&quot;:&quot;bottom&quot;,&quot;ignore&quot;:&quot;&quot;,&quot;reference&quot;:&quot;auto&quot;,&quot;class&quot;:&quot;&quot;,&quot;count&quot;:&quot;0&quot;,&quot;legendonly&quot;:&quot;&quot;,&quot;readonly&quot;:&quot;&quot;,&quot;score&quot;:&quot;0&quot;,&quot;starsonly&quot;:&quot;&quot;,&quot;best&quot;:&quot;5&quot;,&quot;gap&quot;:&quot;5&quot;,&quot;greet&quot;:&quot;Notez cet article&quot;,&quot;legend&quot;:&quot;0\\\/5 - (0 vote)&quot;,&quot;size&quot;:&quot;24&quot;,&quot;title&quot;:&quot;Liver and CBD: what do clinical trials and pharmacovigilance really reveal?&quot;,&quot;width&quot;:&quot;0&quot;,&quot;_legend&quot;:&quot;{score}\\\/{best} - ({count} {votes})&quot;,&quot;font_factor&quot;:&quot;1.25&quot;}'>\n            \n<div class=\"kksr-stars\">\n    \n<div class=\"kksr-stars-inactive\">\n            <div class=\"kksr-star\" data-star=\"1\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"2\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"3\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"4\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" data-star=\"5\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n    <\/div>\n    \n<div class=\"kksr-stars-active\" style=\"width: 0px;\">\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n            <div class=\"kksr-star\" style=\"padding-right: 5px\">\n            \n\n<div class=\"kksr-icon\" style=\"width: 24px; height: 24px;\"><\/div>\n        <\/div>\n    <\/div>\n<\/div>\n                \n\n<div class=\"kksr-legend\" style=\"font-size: 19.2px;\">\n            <span class=\"kksr-muted\">Notez cet article<\/span>\n    <\/div>\n    <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cannabidiol (CBD), a key component of medical cannabis, is generating increasing interest for its potential therapeutic effects. The growing number of clinical trials and the accumulation of pharmacovigilance data are prompting a better understanding of its safety profile, particularly its effect on the liver. What signals are emerging? How should we interpret the drug interactions [&hellip;]<\/p>\n","protected":false},"author":90,"featured_media":14026,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[1019],"tags":[],"class_list":["post-15141","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-around-the-cbd-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Liver and CBD: what do clinical trials and pharmacovigilance really reveal? - CBD Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ud83c\udf31Liver and CBD: what do clinical trials and pharmacovigilance really reveal? - CBD.fr \ud83c\udf31\" \/>\n<meta property=\"og:description\" content=\"Cannabidiol (CBD), a key component of medical cannabis, is generating increasing interest for its potential therapeutic effects. The growing number of clinical trials and the accumulation of pharmacovigilance data are prompting a better understanding of its safety profile, particularly its effect on the liver. What signals are emerging? How should we interpret the drug interactions [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/\" \/>\n<meta property=\"og:site_name\" content=\"CBD Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cbdfrr\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T15:11:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-13T15:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2025\/08\/foie_et_cbd_que_r_v_lent_vraiment_les_essais_cliniques_et_la_pharmacovigilance.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1344\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Julien\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Julien\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Liver and CBD: what do clinical trials and pharmacovigilance really reveal? - CBD Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/","og_locale":"fr_FR","og_type":"article","og_title":"\ud83c\udf31Liver and CBD: what do clinical trials and pharmacovigilance really reveal? - CBD.fr \ud83c\udf31","og_description":"Cannabidiol (CBD), a key component of medical cannabis, is generating increasing interest for its potential therapeutic effects. The growing number of clinical trials and the accumulation of pharmacovigilance data are prompting a better understanding of its safety profile, particularly its effect on the liver. What signals are emerging? How should we interpret the drug interactions [&hellip;]","og_url":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/","og_site_name":"CBD Blog","article_publisher":"https:\/\/www.facebook.com\/cbdfrr\/","article_published_time":"2026-02-13T15:11:58+00:00","article_modified_time":"2026-02-13T15:12:00+00:00","og_image":[{"width":1344,"height":768,"url":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2025\/08\/foie_et_cbd_que_r_v_lent_vraiment_les_essais_cliniques_et_la_pharmacovigilance.webp","type":"image\/webp"}],"author":"Julien","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Julien","Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#article","isPartOf":{"@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/"},"author":{"name":"Julien","@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/person\/d78b472d184ec8ae4135d454e3338c04"},"headline":"Liver and CBD: what do clinical trials and pharmacovigilance really reveal?","datePublished":"2026-02-13T15:11:58+00:00","dateModified":"2026-02-13T15:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/"},"wordCount":1382,"publisher":{"@id":"https:\/\/www.cbd.fr\/blog\/#organization"},"image":{"@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2025\/08\/foie_et_cbd_que_r_v_lent_vraiment_les_essais_cliniques_et_la_pharmacovigilance.webp","articleSection":["Around the CBD"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/","url":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/","name":"Liver and CBD: what do clinical trials and pharmacovigilance really reveal? - CBD Blog","isPartOf":{"@id":"https:\/\/www.cbd.fr\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#primaryimage"},"image":{"@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2025\/08\/foie_et_cbd_que_r_v_lent_vraiment_les_essais_cliniques_et_la_pharmacovigilance.webp","datePublished":"2026-02-13T15:11:58+00:00","dateModified":"2026-02-13T15:12:00+00:00","breadcrumb":{"@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#primaryimage","url":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2025\/08\/foie_et_cbd_que_r_v_lent_vraiment_les_essais_cliniques_et_la_pharmacovigilance.webp","contentUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2025\/08\/foie_et_cbd_que_r_v_lent_vraiment_les_essais_cliniques_et_la_pharmacovigilance.webp","width":1344,"height":768,"caption":"Effets du CBD sur le foie"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cbd.fr\/blog\/liver-and-cbd-what-do-clinical-trials-and-pharmacovigilance-really-reveal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"CBD Blog","item":"https:\/\/www.cbd.fr\/blog\/"},{"@type":"ListItem","position":2,"name":"Around the CBD","item":"https:\/\/www.cbd.fr\/blog\/category\/around-the-cbd-en\/"},{"@type":"ListItem","position":3,"name":"Liver and CBD: what do clinical trials and pharmacovigilance really reveal?"}]},{"@type":"WebSite","@id":"https:\/\/www.cbd.fr\/blog\/#website","url":"https:\/\/www.cbd.fr\/blog\/","name":"CBD Blog","description":"Le meilleur blog de CBD et du chanvre en France par CBD.fr","publisher":{"@id":"https:\/\/www.cbd.fr\/blog\/#organization"},"alternateName":"CBD.fr","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cbd.fr\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.cbd.fr\/blog\/#organization","name":"CBD.fr","alternateName":"CBD.fr","url":"https:\/\/www.cbd.fr\/blog\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2023\/01\/logo-cbd.png","contentUrl":"https:\/\/www.cbd.fr\/blog\/wp-content\/uploads\/2023\/01\/logo-cbd.png","width":215,"height":100,"caption":"CBD.fr"},"image":{"@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cbdfrr\/","https:\/\/www.instagram.com\/cbdfr\/","https:\/\/www.youtube.com\/@CBD_fr","https:\/\/www.linkedin.com\/company\/cbd-fr\/"],"description":"CBD.fr est le leaders fran\u00e7ais du bien-\u00eatre et du CBD, proposant une large gamme de produits \u00e0 base de chanvre rigoureusement s\u00e9lectionn\u00e9s. Expertise, qualit\u00e9 et p\u00e9dagogie sont au c\u0153ur de l\u2019exp\u00e9rience CBD.fr.","email":"support@cbd.fr","telephone":"0189720196","legalName":"CBD.fr","foundingDate":"2021-01-01","taxID":"760933","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"11","maxValue":"50"}},{"@type":"Person","@id":"https:\/\/www.cbd.fr\/blog\/#\/schema\/person\/d78b472d184ec8ae4135d454e3338c04","name":"Julien","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/58f2f1b1e71c329d0226efe2cc40174640e1757e077dac013c980f3ee43c73a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/58f2f1b1e71c329d0226efe2cc40174640e1757e077dac013c980f3ee43c73a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/58f2f1b1e71c329d0226efe2cc40174640e1757e077dac013c980f3ee43c73a0?s=96&d=mm&r=g","caption":"Julien"},"description":"R\u00e9dacteur en chef sp\u00e9cialis\u00e9 en CBD Julien, n\u00e9 le 17 juillet 1978 en r\u00e9gion Parisienne, est un \u00e9minent r\u00e9dacteur et expert dans le domaine des produits \u00e0 base de CBD. Suite \u00e0 ses \u00e9tudes, Julien a d\u00e9velopp\u00e9 une passion pour les rem\u00e8des naturels, dont le CBD. En 2022, il int\u00e8gre l\u2019\u00e9quipe du site CBD.fr en qualit\u00e9 d\u2019expert et de contributeur r\u00e9gulier. Gr\u00e2ce \u00e0 son expertise scientifique et une \u00e9criture claire, Julien aide \u00e0 d\u00e9mystifier les aspects complexes du CBD, tout en mettant en lumi\u00e8re ses bienfaits et applications potentielles \u00e0 travers ses articles et participations \u00e0 des conf\u00e9rences.","honorificPrefix":"Mr","gender":"male","knowsAbout":["CBD","Cannabis","Copywriter"],"knowsLanguage":["French"],"jobTitle":"Editor-in-chief specializing in CBD","worksFor":"CBD.fr","url":"https:\/\/www.cbd.fr\/blog\/author\/redac-cbd\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts\/15141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/users\/90"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/comments?post=15141"}],"version-history":[{"count":1,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts\/15141\/revisions"}],"predecessor-version":[{"id":15142,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/posts\/15141\/revisions\/15142"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/media\/14026"}],"wp:attachment":[{"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/media?parent=15141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/categories?post=15141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cbd.fr\/blog\/wp-json\/wp\/v2\/tags?post=15141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}